Isolation, culture, and immunophenotypic analysis of bone marrow HSPCs from patients with myelodysplastic syndromes

Drug testing assays in hematopoietic stem and progenitor cells (HSPCs) are fundamental in biological studies of myelodysplastic syndromes (MDS) but have historically entailed a technical challenge. This protocol allows the efficient isolation of MDS HSPCs from bone marrow mononuclear cell fractions...

Descripción completa

Detalles Bibliográficos
Autores: Gañán-Gómez, I. (Irene)|||/items/92d1787d-8a7f-414a-af8a-a0cc2094a8af, Clise-Dwyer, K. (Karen)|||/items/c0664b53-8e96-4c11-aa0d-58c0afb8baee, Colla, S. (Simona)|||/items/659f9e93-5695-4c4a-948e-85565d696acc
Tipo de recurso: artículo
Fecha de publicación:2022
País:España
Institución:Universidad de Navarra
Repositorio:Dadun. Depósito Académico Digital de la Universidad de Navarra
Idioma:inglés
OAI Identifier:oai:dadun.unav.edu:10171/121485
Acceso en línea:https://hdl.handle.net/10171/121485
Access Level:acceso abierto
Palabra clave:hematopoietic stem and progenitor cells (HSPCs)
myelodysplastic syndromes (MDS)
Descripción
Sumario:Drug testing assays in hematopoietic stem and progenitor cells (HSPCs) are fundamental in biological studies of myelodysplastic syndromes (MDS) but have historically entailed a technical challenge. This protocol allows the efficient isolation of MDS HSPCs from bone marrow mononuclear cell fractions and their culturing with the support of stromal cells for improved maintenance during drug testing. Lastly, specific steps are given to quantify surviving cells and assess changes in the HSPC hierarchies.